Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial

Linda Rider

Outcomes from the open-label stage of this medical demo provide preliminary evidence that 4 weeks of remedy with a whole-spectrum, substantial-CBD sublingual solution is efficacious in sufferers with moderate-to-extreme stress and anxiety, confirming and extending earlier preclinical and medical exploration6,12. Major reductions for primary result steps of anxiousness had been […]

Subscribe US Now